Newfound Research LLC Trims Holdings in Becton, Dickinson and Company (NYSE:BDX)

Newfound Research LLC trimmed its position in Becton, Dickinson and Company (NYSE:BDXGet Rating) by 16.0% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 408 shares of the medical instruments supplier’s stock after selling 78 shares during the period. Newfound Research LLC’s holdings in Becton, Dickinson and were worth $101,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. HB Wealth Management LLC grew its position in Becton, Dickinson and by 12.8% in the second quarter. HB Wealth Management LLC now owns 14,936 shares of the medical instruments supplier’s stock valued at $3,682,000 after acquiring an additional 1,690 shares in the last quarter. Ritholtz Wealth Management boosted its stake in shares of Becton, Dickinson and by 20.3% during the 2nd quarter. Ritholtz Wealth Management now owns 1,905 shares of the medical instruments supplier’s stock valued at $470,000 after buying an additional 321 shares during the last quarter. YorkBridge Wealth Partners LLC boosted its stake in shares of Becton, Dickinson and by 7.1% during the 2nd quarter. YorkBridge Wealth Partners LLC now owns 3,923 shares of the medical instruments supplier’s stock valued at $967,000 after buying an additional 259 shares during the last quarter. PDS Planning Inc boosted its stake in shares of Becton, Dickinson and by 23.8% during the 2nd quarter. PDS Planning Inc now owns 1,182 shares of the medical instruments supplier’s stock valued at $291,000 after buying an additional 227 shares during the last quarter. Finally, IFM Investors Pty Ltd lifted its stake in Becton, Dickinson and by 5.3% during the second quarter. IFM Investors Pty Ltd now owns 47,938 shares of the medical instruments supplier’s stock worth $11,818,000 after purchasing an additional 2,427 shares during the last quarter. Institutional investors and hedge funds own 86.74% of the company’s stock.

Becton, Dickinson and Stock Down 2.7 %

Shares of Becton, Dickinson and stock traded down $6.34 during trading on Friday, hitting $230.85. 64,798 shares of the stock traded hands, compared to its average volume of 968,418. The stock has a market cap of $65.84 billion, a P/E ratio of 40.89, a PEG ratio of 3.12 and a beta of 0.57. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.90 and a current ratio of 1.35. Becton, Dickinson and Company has a twelve month low of $231.46 and a twelve month high of $280.62. The company has a fifty day moving average price of $252.37 and a two-hundred day moving average price of $253.93.

Becton, Dickinson and (NYSE:BDXGet Rating) last announced its quarterly earnings results on Thursday, August 4th. The medical instruments supplier reported $2.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.50 by $0.16. The business had revenue of $4.64 billion during the quarter, compared to analyst estimates of $4.47 billion. Becton, Dickinson and had a return on equity of 14.55% and a net margin of 8.88%. The firm’s revenue was down 5.1% on a year-over-year basis. During the same period in the previous year, the company earned $2.74 EPS. Equities research analysts predict that Becton, Dickinson and Company will post 11.31 EPS for the current fiscal year.

Becton, Dickinson and Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 30th. Investors of record on Friday, September 9th will be paid a $0.87 dividend. This represents a $3.48 dividend on an annualized basis and a dividend yield of 1.51%. The ex-dividend date is Thursday, September 8th. Becton, Dickinson and’s payout ratio is 60.00%.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the company. Citigroup lowered Becton, Dickinson and from a “neutral” rating to a “sell” rating and dropped their target price for the stock from $265.00 to $235.00 in a research report on Monday, July 11th. Morgan Stanley decreased their price target on Becton, Dickinson and from $282.00 to $272.00 and set an “overweight” rating for the company in a research report on Friday, July 15th. Stifel Nicolaus decreased their price objective on Becton, Dickinson and from $290.00 to $280.00 in a research report on Monday, July 18th. StockNews.com upgraded Becton, Dickinson and from a “hold” rating to a “buy” rating in a research report on Saturday, September 10th. Finally, Wells Fargo & Company upgraded Becton, Dickinson and from an “equal weight” rating to an “overweight” rating and set a $275.00 price objective for the company in a research report on Friday, June 24th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $277.63.

Insider Activity at Becton, Dickinson and

In related news, CEO Thomas E. Polen, Jr. sold 9,500 shares of the firm’s stock in a transaction that occurred on Monday, August 15th. The stock was sold at an average price of $265.13, for a total value of $2,518,735.00. Following the transaction, the chief executive officer now directly owns 28,878 shares of the company’s stock, valued at approximately $7,656,424.14. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Becton, Dickinson and news, EVP Samrat S. Khichi sold 9,185 shares of Becton, Dickinson and stock in a transaction that occurred on Tuesday, August 9th. The stock was sold at an average price of $260.44, for a total value of $2,392,141.40. Following the transaction, the executive vice president now directly owns 5,928 shares of the company’s stock, valued at approximately $1,543,888.32. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Thomas E. Polen, Jr. sold 9,500 shares of Becton, Dickinson and stock in a transaction that occurred on Monday, August 15th. The stock was sold at an average price of $265.13, for a total value of $2,518,735.00. Following the completion of the transaction, the chief executive officer now directly owns 28,878 shares in the company, valued at $7,656,424.14. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 19,160 shares of company stock valued at $5,036,751. Corporate insiders own 0.50% of the company’s stock.

Becton, Dickinson and Profile

(Get Rating)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems.

Further Reading

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.